GLP-1 Evidence

Mechanism

How GLP-1 drugs actually work

The short answer is that they make you less hungry. The longer answer explains why the effect is so much larger than any appetite suppressant that came before.

Updated 4 min read 19 citations Evidence strength 4/5

Ground-floor pharmacy premises on Teltower Damm in Berlin-Zehlendorf, Germany
Singlespeedfahrer · CC0 · Wikimedia Commons

The hormone came first

Glucagon-like peptide-1 is an incretin — a hormone released by cells in your small intestine when food arrives. It tells the pancreas to release insulin, tells the stomach to empty more slowly, and tells the brain that a meal is underway. Native GLP-1 is destroyed within a couple of minutes by an enzyme called DPP-4, which makes it useless as a drug.

Every drug in this class is a modification of that molecule designed to resist DPP-4 and to bind to albumin so the kidneys do not clear it. Semaglutide survives about a week. That is the whole trick: not a new mechanism, but a natural one held open continuously instead of for two minutes after lunch [9][10].

Effect one: you eat less

This is the mechanism that matters for body weight, and it has been measured directly rather than inferred. In controlled feeding studies where participants ate freely from a buffet, semaglutide reduced energy intake substantially and shifted food preference away from high-fat items [8]. A later study with the 2.4 mg obesity dose reproduced the finding and tied it to changes in appetite ratings and control of eating [6].

The comparison that makes the point sharpest is against straightforward calorie restriction. When liraglutide was compared with matched caloric restriction, the appetite-related outcomes differed — the drug was not simply reproducing what dieting does [5].

Reduced energy intake

Effect two: your stomach empties more slowly

Delayed gastric emptying explains a large share of the early fullness people describe, and most of the nausea. A 2024 systematic review and meta-analysis pooled the imaging and breath-test studies and put numbers on it [2] — the delay is real and measurable, but it attenuates with continued exposure, which is consistent with nausea being worst in the first weeks of each dose step.

Effect three: the brain, before the food

The most interesting recent finding is that GLP-1 signalling affects satiation pre-ingestively. Work published in Science identified hypothalamic circuits in which GLP-1 reduces the drive to eat in anticipation of a meal, with converging evidence in humans [11]. That helps explain something users report consistently and which pure gastric-emptying models do not predict: the reduction in food-related rumination, sometimes described as the disappearance of "food noise".

It also fits the emerging signals in other reward-driven behaviours, which we cover on the page about non-weight uses.

Why tirzepatide is different

Tirzepatide is a dual agonist: it activates the GIP receptor as well as the GLP-1 receptor [7]. GIP is the other major incretin, and its role in body weight was contested for years — activating it and blocking it both produced weight loss in different models. Empirically, the dual agonist produces more weight loss than GLP-1 alone [3], but the mechanistic reason is still genuinely unsettled.

Analytical chemistry bench fitted with glassware for titration and pH measurement
Jean-Pierre from Cosne-Cours-sur-Loire (Nièvre, Burgundy… · CC BY-SA 2.0 · Wikimedia Commons

Common questions

Does it speed up my metabolism?
No. The weight loss comes from eating less. Energy expenditure falls as body mass falls, exactly as it does with any other route to weight loss.
Why does the nausea fade?
Gastric emptying delay attenuates with continued dosing [2], which is also why dose escalation is done gradually over months rather than started at the target dose.
Is "food noise" a real thing or a marketing term?
The phrase is informal, but the underlying phenomenon — reduced pre-meal food-related thought — is consistent with the pre-ingestive hypothalamic mechanism identified in [11] and with the appetite-rating changes in [6][8].
Do they work if I do not change what I eat?
The trials all included lifestyle counselling in both arms, so the drug effect is measured on top of advice. But the effect is driven by eating less, which happens whether or not you consciously try.
The evidence behind this page A stacked bar showing the composition of the 19 publications cited on this page by study type. 51031meta-analysis (5)randomised trial (10)review (3)other (1)
19 publications, 2014–2026. That is a mix with both trials and syntheses in it, which is the position from which a claim about cause is reasonable. Source: this page’s own citation list, below.

References

Every citation below links to the original peer-reviewed record on PubMed or via DOI. Nothing here is a substitute for medical advice.

  1. Comparison of Clinical Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients with Obesity and Without T2D: A Bayesian Network Meta-Analysis of Randomised Controlled Trials Ciudin A, Sapin H, Fan L, et al. · Advances in therapy · 2026 · Meta-analysis DOIPubMed 41820778Full text
  2. Effectiveness & safety of semaglutide in weight reduction in obese nondiabetic patients: A systematic review and meta-analysis Naz F, Qaiser F, Mumtaz A, et al. · Medicine · 2026 · Meta-analysis DOIPubMed 42536519Full text
  3. Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement Oprea AD, Ostapenko LJ, Sweitzer B, et al. · British journal of anaesthesia · 2025 · Systematic review DOIPubMed 40379536Full text
  4. Quantified Metrics of Gastric Emptying Delay by Glucagon-Like Peptide-1 Agonists: A Systematic Review and Meta-Analysis With Insights for Periprocedural Management Hiramoto B, McCarty TR, Lodhia NA, et al. · The American journal of gastroenterology · 2024 · Meta-analysis DOIPubMed 38634551Full text
  5. Weight loss efficiency and safety of tirzepatide: A Systematic review Lin F, Yu B, Ling B, et al. · PloS one · 2023 · Meta-analysis DOIPubMed 37141329Full text
  6. A single dose of cannabidiol increases ad libitum energy intake in healthy adults but does not affect postprandial glucose or lipid metabolism Johnson DA, Funnell MP, Cable TG, et al. · Appetite · 2026 · Randomised controlled trial DOIPubMed 41825697
  7. Effects of Sativex(®) Versus Placebo on Glucagon-like Peptide-1, Total Ghrelin, and Subjective Appetite in Older Adults with Poor Appetite: A Protocolized Secondary Analysis of a Double-Blind, Randomized, Placebo-Controlled Crossover Trial Bornæs O, Nielsen RL, Christensen LWS, et al. · Nutrients · 2026 · Randomised controlled trial DOIPubMed 42514343Full text
  8. Effects of Metformin on Postprandial Blood Pressure, Heart Rate, Gastric Emptying, GLP-1, and Prevalence of Postprandial Hypotension in Type 2 Diabetes: A Double-Blind Placebo-Controlled Crossover Study Quast DR, Xie C, Bound MJ, et al. · Diabetes · 2025 · Randomised controlled trial DOIPubMed 39761379
  9. Discovery of ecnoglutide - A novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog Guo W, Xu Z, Zou H, et al. · Molecular metabolism · 2023 · Randomised controlled trial DOIPubMed 37364710Full text
  10. Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes Silver HJ, Olson D, Mayfield D, et al. · Diabetes, obesity & metabolism · 2023 · Randomised controlled trial DOIPubMed 37188932Full text
  11. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity Friedrichsen M, Breitschaft A, Tadayon S, et al. · Diabetes, obesity & metabolism · 2021 · Randomised controlled trial DOIPubMed 33269530Full text
  12. Macronutrient intake, appetite, food preferences and exocrine pancreas function after treatment with short- and long-acting glucagon-like peptide-1 receptor agonists in type 2 diabetes Quast DR, Nauck MA, Schenker N, et al. · Diabetes, obesity & metabolism · 2021 · Randomised controlled trial DOIPubMed 34189834
  13. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept Coskun T, Sloop KW, Loghin C, et al. · Molecular metabolism · 2018 · Randomised controlled trial DOIPubMed 30473097Full text
  14. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity Blundell J, Finlayson G, Axelsen M, et al. · Diabetes, obesity & metabolism · 2017 · Randomised controlled trial DOIPubMed 28266779Full text
  15. GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans van Bloemendaal L, IJzerman RG, Ten Kulve JS, et al. · Diabetes · 2014 · Randomised controlled trial DOIPubMed 25071023
  16. GLP-1 Receptor Agonists Rosen CJ, Ingelfinger JR · The New England journal of medicine · 2026 · Review DOIPubMed 41931049
  17. Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation Moiz A, Filion KB, Tsoukas MA, et al. · The American journal of medicine · 2025 · Review DOIPubMed 39892489
  18. Appetite control and energy balance: impact of exercise Blundell JE, Gibbons C, Caudwell P, et al. · Obesity reviews : an official journal of the International Association for the Study of Obesity · 2015 · Review DOIPubMed 25614205
  19. GLP-1 increases preingestive satiation via hypothalamic circuits in mice and humans Kim KS, Park JS, Hwang E, et al. · Science (New York, N.Y.) · 2024 · Journal article DOIPubMed 38935778Full text